Pratibha Binder, MD, gynecologic oncologist, assistant professor of Obstetrics, Gynecology, and Reproductive Sciences, Moores Cancer Center, UC San Diego Health, discusses how the introduction of novel immune checkpoint inhibitors (ICIs) into frontline treatment strategies could ameliorate unmet needs in endometrial cancer. 

Standard frontline treatment for patients with endometrial cancer involves surgery followed by chemotherapy, radiation therapy, or a combination of the two, Binder says. For patients with a poor performance status who are unable to receive those options, hormone therapy may be considered as an acceptable alternative, according to Binder.

Approaches leveraging ICIs alone or in combination with chemoradiation are being investigated in earlier stages of endometrial cancer treatment, Binder explains. By incorporating these approaches into first-line treatment, or the adjuvant setting, patients may experience fewer adverse effects and better responses— particularly those who are biomarker positive, Binder concludes. 

Videos

Pratibha Binder, MD, discusses how the introduction of novel immune checkpoint inhibitors into frontline treatment strategies could ameliorate unmet needs in endometrial cancer. 

Dr. Binder on the Use of Immune Checkpoint Inhibitors in Endometrial Cancer Treatment 

Pratibha Binder, MD, gynecologic oncologist, assistant professor of Obstetrics, Gynecology, and Reproductive Sciences, Moores Cancer Center, UC San Diego Health, discusses key trials improving the array of treatment options for patients with endometrial cancer.

Treatment options for patients with endometrial cancer were previously limited to chemotherapy, radiation, and endocrine therapy, Binder states. In the past 5 years several trials have shifted this treatment paradigm to incorporate more effective alternatives, such as single-agent checkpoint inhibitors and combination treatments, Binder continues.

Notably, these trials also showed that such treatments did not have to be reserved for later lines. Instead, patients are now able to receive effective treatment immediately after first recurrence or failure of first-line chemotherapy, Binder concludes.

Pratibha Binder, MD, discusses key trials improving the array of treatment options for patients with endometrial cancer.

Pratibha Binder, MD

Articles

Dr. Binder on the Use of Immune Checkpoint Inhibitors in Endometrial Cancer Treatment

Dr. Binder on Key Trials Improving the Treatment Landscape for Endometrial Cancer